Final height and growth hormone secretion after bone marrow transplantation in children.
Growth hormone (GH) deficiency has been regarded as a principal determinant for growth failure following bone marrow transplantation (BMT). We herein analyzed final height and GH secretion in the patients who received BMT during childhood. The study on final height in 30 patients (23 males; 19 with malignant disease) who underwent BMT before or at the onset of puberty showed the following findings: (1) Final height SD score (SDS) significantly decreased compared to pretreatment height SDS. (2) Patients who underwent BMT before the age of 10 years showed significantly greater reduction in height SDS compared to those who received after the age of 10 years. (3) The type of disease or a difference in preconditioning regimen did not influence the outcome of growth. (4) No patient showed GH deficiency. The study on GH secretion included 71 patients who had been followed for more than 5 years and who underwent insulin tolerance test more than twice following BMT. Thirteen patients experienced poor GH response at least once. Two of these patients had poor GH response repeatedly. In conclusion, children who undergo BMT at younger age have a higher risk of growth failure, and GH deficiency is not a major contributing factor for growth impairment following BMT.
Shinagawa
T
T
Department of Pediatrics, Tokai University School of Medicine, Bohseidai, Kanagawa, Japan.
Tomita
Y
Y
Ishiguro
H
H
Matsumoto
M
M
Shimizu
T
T
Yasuda
Y
Y
Hattori
K
K
Kubota
C
C
Yabe
H
H
Yabe
M
M
Kato
S
S
Shinohara
O
O
D000293:Adolescent; D000367:Age Factors; D000741:Anemia, Aplastic / Q000628:therapy; D001827:Body Height; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000453:epidemiology / Q000209:etiology*; D019382:Human Growth Hormone / Q000172:deficiency / Q000378:metabolism*; D006801:Humans; D007328:Insulin; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007938:Leukemia / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D012307:Risk Factors
D007328:Insulin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I